|
2003
OMIG, Abstract 22
OMIG
Main Page | 2003
Abstracts | <
Previous | Next>
Effectiveness
of Fluoroquinolone Antibiotics for Experimental Mycobacterium chelonae
Keratitis
A.R. Caballero, B.A. Thibodeaux, J.J. Dajcs, M.E. Marquart, K.H.
Johnston, J.T. Bush and R.J. O’Callaghan. LSU Health Sciences
Center in New Orleans.
Purpose:
To determine the effectiveness of a new fluoroquinolone
for treating M. chelonae using a rabbit model of keratitis.
Methods: An ATCC strain (19235) or a clinical isolate
(M. chelonae GS) were grown in Middlebrook medium and injected intrastromally
into rabbit corneas (104 CFU). Dexamethasone phosphate was injected
subconjunctivally (2 mg/eye). Antibiotics tested were 0.3% ciprofloxacin
(Ciloxan) and 0.5% moxifloxacin (Vigamox). Eyes were treated topically
with one drop of antibiotic applied hourly for 10 hours on day 3
post-infection (PI) or with one drop applied every two hours for
10 hours on days 1, 2 and 3 PI. Corneas were harvested and cultured
one hour after the last topical drop.
Results: Untreated controls of strain 19235 maintained
4 logs CFU/ cornea for 3 days then underwent a steady decline to
less than 1 log CFU by day 12. Clinical strain GS increased in numbers
in the cornea and grew to 6 logs CFU/cornea by day 3. Treatment
of strain 19235 on day 3 PI resulted in 0.3 and 1.33 log reductions
in CFU/cornea for ciprofloxacin and moxifloxacin, respectively,
relative to the untreated control (4.17 logs). Treatment of eyes
infected with strain GS on days 1 to 3 with moxifloxacin resulted
in 5.76 log reduction in CFU/cornea relative to the untreated control
(6.24 logs). Moxifloxacin significantly reduced the numbers of Mycobacteria
in the cornea for strains 19235 and GS (P<0.0001).
Conclusion: Moxifloxacin demonstrated significant
effectiveness for treating experimental mycobacterial keratitis.
Supported by LSUHSC Foundation (thanks to a donation from Alcon
Laboratories, Inc.) and NEI grant EY10974.
OMIG
Main Page | 2003
Abstracts | <
Previous | Next>
|
|
|